Abstract

During lung fibrosis, the epithelium induces signaling to underlying mesenchyme to generate excess myofibroblasts and extracellular matrix; herein, we focus on signaling in the mesenchyme. Our studies indicate that platelet-derived growth factor receptor (PDGFR)-β+ cells are the predominant source of myofibroblasts and Kruppel-like factor (KLF) 4 is upregulated in PDGFR-β+ cells, inducing TGFβ pathway signaling and fibrosis. In fibrotic lung patches, KLF4 is down-regulated, suggesting KLF4 levels decrease as PDGFR-β+ cells transition into myofibroblasts. In contrast to PDGFR-β+ cells, KLF4 reduction in α-smooth muscle actin (SMA)+ cells non-cell autonomously exacerbates lung fibrosis by inducing macrophage accumulation and pro-fibrotic effects of PDGFR-β+ cells via a Forkhead box M1 to C-C chemokine ligand 2—receptor 2 pathway. Taken together, in the context of lung fibrosis, our results indicate that KLF4 plays opposing roles in PDGFR-β+ cells and SMA+ cells and highlight the importance of further studies of interactions between distinct mesenchymal cell types.

The pluripotency factor KLF4 has been described as pro-fibrotic or anti-fibrotic in various diseases. Herein, the authors show that during lung fibrosis, these distinct effects can be attributed to mesenchymal cell-type specific functions of KLF4.

Details

Title
Distinct roles of KLF4 in mesenchymal cell subtypes during lung fibrogenesis
Author
Chandran, Rachana R 1 ; Xie, Yi 2   VIAFID ORCID Logo  ; Gallardo-Vara Eunate 1   VIAFID ORCID Logo  ; Adams, Taylor 3 ; Garcia-Milian, Rolando 4   VIAFID ORCID Logo  ; Kabir Inamul 1   VIAFID ORCID Logo  ; Sheikh, Abdul Q 5 ; Kaminski Naftali 3   VIAFID ORCID Logo  ; Martin, Kathleen A 2 ; Herzog, Erica L 6 ; Greif, Daniel M 1   VIAFID ORCID Logo 

 Yale University School of Medicine, Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale University School of Medicine, Department of Genetics, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710) 
 Yale University School of Medicine, Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale University School of Medicine, Department of Pharmacology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710) 
 Yale University School of Medicine, Section of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710) 
 Yale University School of Medicine, Bioinformatics Support Program, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710) 
 Yale University School of Medicine, Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Pfizer, Cambridge, USA (GRID:grid.410513.2) (ISNI:0000 0000 8800 7493) 
 Yale University School of Medicine, Section of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale University School of Medicine, Department of Pathology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2608620732
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.